A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis.
In this study, we sought to determine whether liposomal preparations containing a phospholipid conjugate of methotrexate and dimyristoylphosphatidylethanolamine (MTX-gamma-DMPE) incorporated within their lipid membranes are effective in suppressing established joint inflammation in a monoarticular model of arthritis in the rat. Arthritis was induced in the right knee joint of Lewis rats. The rats were treated with a single intra-articular injection of either free methotrexate (MTX), liposomal MTX [MTX-multilamellar vesicles (MLV)-1.2 microns or MTX-small unilamellar vesicles (SUV)-100 nm], control liposomes (E-LIPO) or saline into the inflamed knee 7 days after arthritis induction. There was no significant difference in knee swelling in MTX-, saline- and E-LIPO-treated rats up to 21 days after treatment. However, MTX-MLV treatment produced a significant reduction in knee swelling (26.5 +/- 6.0%: mean +/- S.E.M.) 1 day after intra-articular injection compared with MTX (3.5 +/- 3.5%) and MTX-SUV (14.4 +/- 2.4%), respectively. Over the next 20 days, knee swelling in MTX-MLV-treated rats fell progressively and almost returned to normal. MTX-MLV treatment also inhibited the cellular infiltration associated with the arthritis. Large multilamellar liposomal preparations of MTX-gamma-DMPE are more effective than free MTX and MTX-SUV in suppressing inflammation. Their differential effects in treating the antigen-induced arthritis model are related to their retention within the joint space.
Williams
A S
AS
Rheumatology Research Laboratory, University of Wales College of Medicine, Heath Park, Cardiff.
Camilleri
J P
JP
Goodfellow
R M
RM
Williams
B D
BD
D000818:Animals; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001168:Arthritis / Q000139:chemically induced / Q000150:complications / Q000517:prevention & control*; D004337:Drug Carriers; D007270:Injections, Intra-Articular; D008081:Liposomes; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000493:pharmacokinetics; D051381:Rats; D011917:Rats, Inbred Lew; D012710:Serum Albumin, Bovine; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D004337:Drug Carriers; D008081:Liposomes; D010714:Phosphatidylethanolamines; D012710:Serum Albumin, Bovine; D008727:Methotrexate; C018525:1,2-dimyristoylphosphatidylethanolamine